Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06372821 · ClinicalTrials.gov registry record · Phase 1
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
A Phase 1 study of Alzheimer Disease and Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), sponsored by University College, London.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06372821: Recruiting Phase 1 study of Alzheimer Disease and Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), sponsored by University College, London.
NCT06372821 is a Phase 1 study of Alzheimer Disease and Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) that is actively recruiting participants, run by University College, London. The registered enrollment target is 10 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06372821, a Phase 1 study of Alzheimer Disease and Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), is actively recruiting participants, sponsored by University College, London.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.
Primary Outcome
Tau synthesis rate calculated using tracer to tracee ratio of tau specific peptide calculated on day 20 post leucine administration in individuals with sporadic and ADAD (analyzed collectively) receiving intrathecal NIO752 compared to placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG NIO752
Study Locations (2)
Missouri
- Washington University in St. Louis - St Louis
Other
- University College London Hospitals NHS Foundation Trust - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT06372821 shows while recruiting
NCT06372821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06372821 reports a single indexed study location in Missouri, Other.
Frequently Asked Questions
What is clinical trial NCT06372821 about?
NCT06372821 is a clinical study titled "A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK". This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cel...
What is the current status of trial NCT06372821?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-11-18. Estimated completion is 2026-07.
What conditions does trial NCT06372821 study?
This clinical trial studies the following conditions: Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder).
What interventions are being tested in trial NCT06372821?
The interventions under investigation include: Placebo (OTHER), NIO752 (DRUG).
Who is sponsoring clinical trial NCT06372821?
This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06372821 being conducted?
This trial has 2 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06372821's enrollment target sits among peer trials
10 291st of 306 higher than 13 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI